Lipocine Inc. Share Price
NASDAQ: LPCN | Micro CapLipocine Inc. Stock Performance
Open $2.13 | Prev. Close $2.18 | Circuit Range N/A |
Day Range $2.13 - $2.13 | Year Range $1.81 - $12.35 | Volume 246 |
Average Traded $2.13 |
Lipocine Inc. Share Price Today
As of 7 August 2026, Lipocine Inc.'s share price is $2.15. The stock opened at $2.13, compared to its previous close of $2.18. During today's trading session, Lipocine Inc.'s share price traded between $2.13 and $2.13, with an average price of $2.13. Over the past 52 weeks, the stock has recorded a high of $12.35 and a low of $1.81. In terms of performance, Lipocine Inc.'s share price has declined by 78.36% over the last six months and is down 26.20% on a year-on-year basis.
Lipocine Inc. Share Price Chart
Lipocine Inc. Stock Fundamentals & Key Indicators
Market Cap $11.74M | PE Ratio (TTM) -1.22 | Dividend Yield N/A |
EPS (TTM) $-1.77 | Revenue (TTM) $1.98M | Return On Equity (TTM) -66.50% |
Profit Margin -487.06% | Debt to Equity 0.17 | Quarterly Earnings Growth YoY -3.85% |
Lipocine Inc. Quarterly Profit & Loss
All figures in USD
Lipocine Inc. Annual Profit & Loss
All figures in USD
About Lipocine Inc.
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation long-acting oral product candidate for TRT; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the treatment of cirrhosis; LPCN 1154 to treat postpartum depression; LPCN 2101, a NAS candidate for women with epilepsy; and LPCN 2203, an oral candidate for management of essential tremor. It also develops LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of metabolic dysfunction-associated steatohepatitis; LPCN 2401 to improve body composition in obesity management; and LPCN 1107, an oral hydroxy progesterone caproate product indicated for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.
Lipocine Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $2.10 | $2.18 | +3.32% |
Jul 2026 | $2.46 | $2.11 | -18.53% |
Jun 2026 | $2.28 | $2.59 | +14.10% |
May 2026 | $2.38 | $2.27 | -3.40% |
Apr 2026 | $7.89 | $2.35 | -70.25% |
Mar 2026 | $9.35 | $7.90 | -20.68% |
Feb 2026 | $8.06 | $9.96 | +10.67% |
Jan 2026 | $8.02 | $9.00 | +10.02% |
Dec 2025 | $3.10 | $8.18 | +150.92% |
Nov 2025 | $2.66 | $3.26 | +23.02% |
Oct 2025 | $2.93 | $2.65 | -6.03% |
Sep 2025 | $3.00 | $2.82 | -3.42% |
LPCN Share Price FAQs
What is Lipocine Inc. share price today?
What is the 52 week high and 52 week low of Lipocine Inc. stock?
What is LPCN's market capitalisation today?
What is LPCN's net income for the last quarter?
What is the 5 year returns of LPCN?
What is the high & low stock price of LPCN today?
Can I buy LPCN shares in India?